Illumina, Inc. (ILMN)
NASDAQ: ILMN · Real-Time Price · USD
99.86
-0.25 (-0.25%)
Oct 27, 2025, 1:10 PM EDT - Market open
Illumina Employees
Illumina had 10,370 employees as of December 31, 2024. The number of employees decreased by 2,020 or -16.30% compared to the previous year.
Employees
10,370
Change (1Y)
-2,020
Growth (1Y)
-16.30%
Revenue / Employee
$413,115
Profits / Employee
$121,215
Market Cap
15.36B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 10,370 | -2,020 | -16.30% |
| Dec 31, 2023 | 12,390 | -970 | -7.26% |
| Dec 31, 2022 | 13,360 | 1,610 | 13.70% |
| Dec 31, 2021 | 11,750 | 2,400 | 25.67% |
| Dec 31, 2020 | 9,350 | 1,650 | 21.43% |
| Dec 29, 2019 | 7,700 | 400 | 5.48% |
| Dec 30, 2018 | 7,300 | 1,100 | 17.74% |
| Dec 31, 2017 | 6,200 | 700 | 12.73% |
| Dec 31, 2016 | 5,500 | 900 | 19.57% |
| Dec 31, 2015 | 4,600 | 900 | 24.32% |
| Dec 28, 2014 | 3,700 | 700 | 23.33% |
| Dec 29, 2013 | 3,000 | 800 | 36.36% |
| Dec 31, 2012 | 2,200 | -200 | -8.33% |
| Dec 30, 2012 | 2,400 | 300 | 14.29% |
| Dec 31, 2011 | 2,100 | 319 | 17.91% |
| Dec 31, 2010 | 1,781 | 245 | 15.95% |
| Dec 28, 2008 | 1,536 | 495 | 47.55% |
| Dec 30, 2007 | 1,041 | 445 | 74.66% |
| Dec 31, 2006 | 596 | 221 | 58.93% |
| Dec 31, 2005 | 375 | 97 | 34.89% |
| Dec 31, 2004 | 278 | 42 | 17.80% |
| Dec 28, 2003 | 236 | 3 | 1.29% |
| Dec 29, 2002 | 233 | 54 | 30.17% |
| Dec 30, 2001 | 179 | 74 | 70.48% |
| Dec 31, 2000 | 105 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ILMN News
- 5 days ago - Illumina: Innovation Outweighs Short-Term Risks - A Long-Term Buy Ahead Of Q3 Earnings - Seeking Alpha
- 12 days ago - Illumina fuels multiomic discovery with launch of 5-base solution, unlocking simultaneous genomic and epigenomic insights - PRNewsWire
- 12 days ago - Illumina constellation mapped read technology uncovers hard-to-see genomic insights in GeneDx pilot - PRNewsWire
- 12 days ago - Illumina to Announce Third Quarter 2025 Financial Results on Thursday, October 30, 2025 - PRNewsWire
- 26 days ago - Illumina launches new business to accelerate technology and data-driven discovery - PRNewsWire
- 4 weeks ago - ILMN Stock vs. IQV Stock - Forbes
- 4 weeks ago - Illumina advances personalized cancer care with new pharma development partnerships - PRNewsWire
- 5 weeks ago - Alnylam Pharmaceuticals joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicine - PRNewsWire